In Australia, you can’t patent human DNA or gene sequences, but the current system still allows patents for many types of biological materials. It’s a complex and contentious subject, and many legal changes have altered the map of gene patents in Australia.
The rules now make a clear difference between unpatentable discoveries and legitimate inventions. That means synthetic DNA sequences, isolated proteins, genetically modified organisms, and methods with genetic material can still be patented. This difference helps patent law balance the public interest while still giving medical researchers a financial incentive.
Australian inventors must meet specific legal requirements to get patent protection. These requirements focus on what qualifies as patentable subject matter, which both legislation and landmark court decisions have shaped.
The lifeblood of patentability in Australia requires an invention to be a ‘manner of manufacture’ as defined in the Patents Act 1990. A patentable invention must meet these criteria:
In Australia, a gene patent is a type of intellectual property right that gives the patent holder exclusive control over the commercial use of a specific genetic material they have isolated or modified. While naturally occurring genes cannot be patented in their unaltered form, isolated genetic sequences, methods of using them, or applications of genetic information may be patentable if they meet the usual patent criteria.
Understanding the statistics about Australian gene patents can be challenging. Australian inventors submit roughly 2% of biotechnology patent applications in Australia, with most applications coming overseas from the United States.
Of the applications filed by Australian organisations, most were from corporations and universities, with not-for-profit entities and government agencies contributing smaller numbers.
Biological materials must meet one of these criteria to qualify for patent eligibility in Australia:
The biological invention must show a specific use and explain how it’s different from natural source material. Pure cultures or isolations from technical intervention might qualify for patent protection, while natural microorganisms remain unpatentable as mere discoveries.
The groundbreaking legal battle over gene patents in Australia started in 2010. Cancer Voices Australia and breast cancer survivor Yvonne D’Arcy challenged Myriad Genetics’ patent rights to the BRCA1 gene.
The Federal Court of Australia upheld Myriad’s patent claims at first. Justice Nicholas determined that genetic material could only exist through human intervention once extracted from its natural cellular environment. This made it an “artificially created state of affairs” with “economic significance”. The Full Federal Court later backed this decision and stated that isolated DNA was patentable subject matter in Australia.
D’Arcy’s appeal led to a unanimous decision by the High Court of Australia, which overturned the lower courts’ rulings. The justices pointed out that Myriad had found the BRCA1 gene’s location and mutations, but hadn’t created or changed the genetic information, concluding that isolated sequences held information similar to natural DNA.
The ruling set clear legal limits on genetic materials that qualify as inventions. The Court made a clear distinction between gene sequences and methods that use these sequences, preserving patent rights for diagnostic methods and applications of genetic information. The decision brought broader policy considerations into patent determinations, including how they affect breakthroughs and balance public and private interests.
Australia still allows patents for many types of biological materials that meet certain criteria.
IP Australia accepts patents for synthetic DNA sequences not found in any living organism’s genome. Isolated proteins from genes can still be patented. So while natural genetic sequences can’t be patented, their protein products and artificial genetic material remain eligible.
Many genetically modified biological inventions qualify for patent protection, such as:
Despite restrictions on gene patents, methods with genetic materials remain protected. Scientists can patent diagnostic techniques, genetic transformation processes, and industrial processes that use specific genes.
The Australian patent landscape has changed since the Myriad decision, creating clearer boundaries for researchers and opening new paths for state-of-the-art developments.
It is impossible to patent genetic information that exists organically in genes, even with artificial manipulation. IP Australia now clearly states that patents cannot be granted for gene sequences, DNA, RNA or nucleic acid sequences that copy genetic information from any organism’s genome. This applies whatever the material’s origin: isolated or man-made.
Several reform proposals need review. The Australian Law Reform Commission advised against excluding genetic materials from patentability but supported stronger ‘usefulness’ assessment criteria. The Senate Community Affairs Committee concluded that the Patents Act should stay unchanged regarding gene patents. They preferred to keep patent laws neutral towards technology. The Productivity Commission promotes better safeguards, including compulsory licensing provisions for patented inventions that affect healthcare access.
Australia’s gene patent legislation has changed dramatically, and the system will likely keep changing as biotechnology moves forward. Researchers who want to turn their findings into protected assets must stay aware of these legal limits, and Kings IP is here to help.
As experienced IP attorneys, our team brings together broad IP expertise with specialist knowledge of the life sciences industry. This makes us well placed to advise you on gene patenting in Australia, from assessing patentability through to building a protection strategy around your research and commercial goals.
Partner with our experts and protect the innovation you’ve worked hard to develop, today and into the future.
